Which antiplatelet medication is specifically indicated for intermittent claudication?

Cilostazol is specifically indicated for the treatment of intermittent claudication, a condition characterized by muscle pain in the legs during physical activity due to inadequate blood flow. Cilostazol works primarily as a phosphodiesterase III inhibitor, leading to vasodilation and improved blood flow, which helps alleviate the symptoms of claudication. This makes it a unique choice among antiplatelet medications as it not only inhibits platelet aggregation but also directly improves blood circulation in the affected limbs.

The other medications listed have different primary uses. For example, eptifibatide is a glycoprotein IIb/IIIa inhibitor used primarily in acute coronary syndrome and during percutaneous coronary interventions, rather than for managing claudication. Aspirin and clopidogrel are both well-known antiplatelet agents used to reduce the risk of cardiovascular events, particularly in patients with a history of heart disease or stroke. While they may have some benefit in patients with peripheral artery disease, they are not specifically indicated for treating intermittent claudication. Thus, cilostazol stands out as the appropriate medication for this specific condition.